SCHEMBL129599

SCHEMBL129599

COc1c(F)cc(-c2nn(C)c3ncnc(N)c23)cc1F

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 19/20 0.59
PIK3CG P48736 19/20 0.59
PRKDC P78527 19/20 0.59
PIK3CD O00329 18/20 0.59
PIK3CA P42336 18/20 0.59
ABL1 P00519 16/20 0.59
EGFR P00533 16/20 0.59
HCK P08631 16/20 0.59
SRC P12931 16/20 0.59
MTOR P42345 16/20 0.59
EPHB4 P54760 16/20 0.59
PI4KB Q9UBF8 7/20 0.59
KDR P35968 15/20 0.54
NUDT14 O95848 1/20 0.53
NUDT5 Q9UKK9 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128507 0.86 SRC (0.60) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL129595 0.84 PIK3CD (0.62) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL218160 0.84 SRC (0.75) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL129883 0.84 PIK3CD (0.74) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL23917223 0.84 PIK3CB (0.56) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL129505 0.83 PIK3CD (0.62) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL130486 0.82 PIK3CD (0.63) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL23917454 0.81 PIK3CD (0.65) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL21436578 0.81 PIK3CD (0.65) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA
SCHEMBL30320603 0.81 PIK3CD (0.65) PIK3CBPIK3CGPRKDCPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-10322130-B2 Substituted chromenones as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-06-18 US disclosed
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-04-11 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 PIK3CB 1/4885PIK3CG 15/4885PRKDC 244/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CB 33/4885PIK3CG 99/4885PRKDC 164/4885
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CB 23/4885PIK3CG 77/4885PRKDC 141/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CB 23/4885PIK3CG 77/4885PRKDC 141/4885
US-20190105324-A9 SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKAR2B PIK3CB 83/4885PIK3CG 128/4885PRKDC 178/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB PIK3CB 23/4885PIK3CG 77/4885PRKDC 141/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CB 33/4885PIK3CG 99/4885PRKDC 164/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CB 33/4885PIK3CG 99/4885PRKDC 164/4885
US-10322130-B2 Substituted chromenones as modulators of protein kinases MAP3K1, CSNK1A1, MAP3K2 PIK3CB 181/4885PIK3CG 194/4885PRKDC 325/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A PIK3CB 102/4885PIK3CG 126/4885PRKDC 253/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CB 33/4885PIK3CG 99/4885PRKDC 164/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB PIK3CB 33/4885PIK3CG 99/4885PRKDC 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.